These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 29051803)

  • 1. Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
    Gallogly MM; Lazarus HM; Cooper BW
    Ther Adv Hematol; 2017 Sep; 8(9):245-261. PubMed ID: 29051803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
    Kayser S; Levis MJ; Schlenk RF
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Midostaurin: an emerging treatment for acute myeloid leukemia patients.
    Gallogly MM; Lazarus HM
    J Blood Med; 2016; 7():73-83. PubMed ID: 27186148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis.
    Schlenk RF; Kayser S
    Recent Results Cancer Res; 2018; 212():199-214. PubMed ID: 30069632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
    Stansfield LC; Pollyea DA
    Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis.
    Stone RM; Manley PW; Larson RA; Capdeville R
    Blood Adv; 2018 Feb; 2(4):444-453. PubMed ID: 29487059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis.
    Sly N; Gaspar K
    Am J Health Syst Pharm; 2019 Feb; 76(5):268-274. PubMed ID: 30753289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy.
    Weisberg E; Sattler M; Manley PW; Griffin JD
    Onco Targets Ther; 2018; 11():175-182. PubMed ID: 29343975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
    Garcia JS; Percival ME
    Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection.
    Abbas HA; Alfayez M; Kadia T; Ravandi-Kashani F; Daver N
    Cancer Manag Res; 2019; 11():8817-8828. PubMed ID: 31632141
    [No Abstract]   [Full Text] [Related]  

  • 13. Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia.
    Wang ES
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):154-162. PubMed ID: 31203997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Midostaurin: Nursing Perspectives on Managing Treatment and Adverse Events in Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia and Advanced Systemic Mastocytosis.
    Galinsky I; Coleman M; Fechter L
    Clin J Oncol Nurs; 2019 Dec; 23(6):599-608. PubMed ID: 31730602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDM2- and FLT3-inhibitors in the treatment of
    Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
    Haematologica; 2018 Nov; 103(11):1862-1872. PubMed ID: 29976747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin.
    Arnán Sangerman M; Fernández Moreno A; García Quintana A; García-Vidal C; Olave Rubio MT; Del Mar Tormo Díaz M; Vendranas M; Rodriguez Macias G
    Expert Rev Hematol; 2022 Mar; 15(3):203-214. PubMed ID: 35332831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment practice and outcomes in
    Chua CC; Grigg A; Singh J; Droogleever MP; Zhang L; Lim A; Fong CY; Ting SB; Schwarer A; Tiong IS; Wei AH
    Leuk Lymphoma; 2020 Apr; 61(4):848-854. PubMed ID: 31752581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Midostaurin for the treatment of acute myeloid leukemia.
    Patnaik MM
    Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells.
    Tvedt TH; Nepstad I; Bruserud Ø
    Expert Opin Investig Drugs; 2017 Mar; 26(3):343-355. PubMed ID: 28001095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.